We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Link Technologies Inks Exclusive License to Agilent Technologies’ TC RNA Monomers
News

Link Technologies Inks Exclusive License to Agilent Technologies’ TC RNA Monomers

Link Technologies Inks Exclusive License to Agilent Technologies’ TC RNA Monomers
News

Link Technologies Inks Exclusive License to Agilent Technologies’ TC RNA Monomers

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Link Technologies Inks Exclusive License to Agilent Technologies’ TC RNA Monomers"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The specialist oligonucleotide reagent manufacturer, Link Technologies Limited, has announced the commercialization and launch of TC RNA Monomers under exclusive license with Agilent Technologies Inc. Under the terms of the agreement Link will manufacture and sell the four RNA monomer phosphoramidite reagents for use in research. No financial details of the agreement have been disclosed.

The reagents are being launched at TIDEs (Las Vegas) on May 18, where Dr Douglas Dellinger, Principal Investigator at Agilent Technologies, will present a technology workshop entitled “The Development of a Cost-Effective Large Scale Synthesis Process for RNA Therapeutics”.

These monomers can offer significant advantages over existing RNA chemistry including lower cost amidites, reduced synthesis cycle times, high-percentage full-length product and a simple one-step base cleavage and deprotection procedure.

“Agilent is committed to enabling cost-effective manufacturing of siRNA therapeutics at commercial-scale.” said James Powell, general manager of Agilent's Nucleic Acid Solutions Division. “This exclusive distribution agreement with Link Technologies for research-scale quantities of our innovative TC protection chemistry monomers is the first step towards that goal.”

Managing Director of Link Technologies, Dr Mike Gray also added: "This agreement heralds an important milestone for Link Technologies. Successfully delivering Agilent’s innovative chemistry to the research market at an early stage underlines our capability in this field, thus enabling widespread early adoption and application of the new technology”.
Advertisement